Evidence map›Paper›PMID 26269289›Full record

ReviewDer Nervenarzt2015

[Current aspects of therapy conversion for multiple sclerosis].

P Kolber, F Luessi, S G Meuth, L Klotz, T Korn, C Trebst, B Tackenberg, B Kieseier, T Kümpfel, V Fleischer and 15 more

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Der Nervenarzt, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

P KolberKlinik und Poliklinik für Neurologie, Forschungszentrum Translationale Neurowissenschaften (FTN), Forschungszentrum für Immuntherapie (FZI), Rhine Main Neuroscience Network (rmn2), Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, 55101, Mainz, Deutschland.
F LuessiKlinik und Poliklinik für Neurologie, Forschungszentrum Translationale Neurowissenschaften (FTN), Forschungszentrum für Immuntherapie (FZI), Rhine Main Neuroscience Network (rmn2), Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, 55101, Mainz, Deutschland. luessi@uni-mainz.de.
S G MeuthKlinik für Allgemeine Neurologie, Universitätsklinikum Münster, Münster, Deutschland.
L KlotzKlinik für Allgemeine Neurologie, Universitätsklinikum Münster, Münster, Deutschland.
T KornNeurologische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München; Munich Cluster for Systems Neurology (SyNergy), München, Deutschland.
C TrebstKlinik für Neurologie, Medizinische Hochschule Hannover, Hannover, Deutschland.
B TackenbergKlinik für Neurologie, Klinische Neuroimmunologie, Universitätsklinikum Gießen und Marburg, Marburg, Deutschland.
B KieseierNeurologische Klinik, Universitätsklinikum der Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Deutschland.
T KümpfelInstitut für Klinische Neuroimmunologie, Klinikum der Universität München, Munich Cluster for Systems Neurology (SyNergy), München, Deutschland.
V FleischerKlinik und Poliklinik für Neurologie, Forschungszentrum Translationale Neurowissenschaften (FTN), Forschungszentrum für Immuntherapie (FZI), Rhine Main Neuroscience Network (rmn2), Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, 55101, Mainz, Deutschland.
H TumaniKlinik für Neurologie, Universitätsklinikum Ulm, Ulm, Deutschland.
B WildemannNeurologische Klinik, Universitätsklinikum Heidelberg, Heidelberg, Deutschland.
M LangNeuroPoint Patientenakademie, Ulm, Deutschland.
P FlacheneckerNeurologisches Rehabilitationszentrum Quellenhof, Bad Wildbad, Deutschland.
U MeierNeuroCentrum, Grevenbroich, Deutschland.
W BrückAbtl. Neuropathologie, Universitätsmedizin Göttingen der Georg-August-Universität Göttingen, Göttingen, Deutschland.
V LimmrothKlinik für Neurologie und Palliativmedizin, Kliniken der Stadt Köln, Köln, Deutschland.
A HaghikiaSt. Josef-Hospital, Universitätsklinikum der Ruhr-Universität Bochum, Bochum, Deutschland.
H-P HartungNeurologische Klinik, Universitätsklinikum der Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Deutschland.
M StangelAbt. Klinische Neuroimmunologie und Neurochemie, Klinik für Neurologie, Medizinische Hochschule Hannover, Zentrum für Systemische Neurowissenschaften Hannover (ZSN), Hannover, Deutschland.
R HohlfeldInstitut für Klinische Neuroimmunologie, Klinikum der Universität München, Munich Cluster for Systems Neurology (SyNergy), München, Deutschland.
B HemmerNeurologische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München; Munich Cluster for Systems Neurology (SyNergy), München, Deutschland.
R GoldSt. Josef-Hospital, Universitätsklinikum der Ruhr-Universität Bochum, Bochum, Deutschland.
H WiendlKlinik für Allgemeine Neurologie, Universitätsklinikum Münster, Münster, Deutschland.
F ZippKlinik und Poliklinik für Neurologie, Forschungszentrum Translationale Neurowissenschaften (FTN), Forschungszentrum für Immuntherapie (FZI), Rhine Main Neuroscience Network (rmn2), Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, 55101, Mainz, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years the approval of new substances has led to a substantial increase in the number of course-modifying immunotherapies available for multiple sclerosis. Therapy conversion therefore represents an increasing challenge. The treatment options sometimes show complex adverse effect profiles and necessitate a long-term and comprehensive monitoring. This article presents an overview of therapy conversion of immunotherapies for multiple sclerosis in accordance with the recommendations of the Disease-Related Competence Network for Multiple Sclerosis and the German Multiple Sclerosis Society as well as the guidelines on diagnostics and therapy for multiple sclerosis of the German Society of Neurology and the latest research results. At the present point in time it should be noted that no studies have been carried out for most of the approaches for therapy conversion given here; however, the recommendations are based on theoretical considerations and therefore correspond to recommendations at the level of expert consensus, which is currently essential for the clinical daily routine.

Indexed as

Practice Guidelines as TopicAllergy and ImmunologyDose-Response Relationship, DrugDrug Administration ScheduleGermanyHumansImmunosuppressive AgentsImmunotherapyMultiple SclerosisNeurologyImmunosuppressive AgentsClinical routineDisease-related competence network multiple sclerosisExpert consensusImmunotherapyWashout phase

Identifiers

PMID26269289

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.